5-Amino-1MQ
PreclínicoNNMT Inhibitor | Longevity & Metabolic Enhancement
5-Amino-1MQ is a small molecule NNMT (nicotinamide N-methyltransferase) inhibitor that enhances cellular NAD+ levels and mitochondrial function.
Datos moleculares y de investigación
- Vida media
- 4-7 hours (3.8h IV, 6.9h oral)
- Rutas (investigación)
- oral, injectable
- Almacenamiento
- Oral: room temp. Injectable: lyophilized room temp or freezer, reconstituted 2-8°C for 28 days
Overview
5-Amino-1MQ is a small molecule NNMT (nicotinamide N-methyltransferase) inhibitor that enhances cellular NAD+ levels and mitochondrial function. Not a true peptide, but a small molecule compound used in longevity and metabolic optimization protocols.
Mechanism of action
Inhibits NNMT enzyme systemically, preventing NAD+ degradation and maintaining elevated cellular NAD+ levels to support mitochondrial function and metabolic processes.
Key research findings
- Enhanced NAD+ levels
- Improved mitochondrial function
- Better energy metabolism
- Enhanced cellular repair
- Improved insulin sensitivity
- Longevity support
- Convenient daily oral dosing
Research applications
Longevity
- NAD+ Enhancement — Significantly increases cellular NAD+ levels by inhibiting NNMT enzyme, supporting cellular energy production and DNA repair mechanisms essential for healthy aging.
- Mitochondrial Function — Improves mitochondrial biogenesis and efficiency, enhancing cellular energy production and reducing oxidative stress markers associated with aging.
- Cellular Repair — Enhanced NAD+ availability supports sirtuins and other longevity pathways involved in DNA repair, cellular maintenance, and stress resistance.
Metabolism
- Energy Metabolism — Improvement through enhanced mitochondrial efficiency.
- Insulin Sensitivity — Enhancement via cellular energy optimization.
- Metabolic Flexibility — Improved glucose/fat substrate switching.
Weight Loss
- Metabolic Rate Enhancement — Supports increased basal metabolic rate.
- Fat Oxidation — Improvements in fat burning capacity.
Preguntas frecuentes sobre 5-Amino-1MQ
What is the difference between the mcg and mg protocols for 5-Amino-1MQ injection?+
Two vastly different dosing protocols exist differing by 100-200x: the mcg protocol uses 150-500mcg daily while the mg protocol uses ~350mg (5mg/kg) daily. This massive discrepancy creates serious overdose risk. Always verify units (mcg vs mg) before reconstitution to avoid a potentially 100+ fold dosing error.
Does 5-Amino-1MQ actually increase NAD+ levels in humans?+
Animal studies demonstrate significant NAD+ elevation through NNMT inhibition. A 2024 study showed aged mice treated with 5A1MQ gained ~40% greater grip strength vs controls, with improved intramuscular lipid content and muscle fiber cross-sectional area, providing evidence that NAD+ enhancement translates to functional improvements.
Can I take 5-Amino-1MQ with food or does it need to be on an empty stomach?+
Take 5-Amino-1MQ with food to improve absorption and reduce potential GI effects. Consistent daily timing helps maintain steady NAD+ levels, and morning or early afternoon dosing is preferred to avoid potential sleep interference.
What's the timeline for seeing metabolic benefits from 5-Amino-1MQ?+
Week 1-2 shows gradual energy increase and mental clarity. Week 2-4 brings enhanced exercise performance and recovery. Week 4-8 shows improved metabolic markers and body composition changes. Peak longevity benefits with sustained cellular health improvements appear by week 8-12 with continuous use.
References
- [1]Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in miceBiochemical Pharmacology
- [2]Development & validation of LC-MS/MS assay for 5-amino-1-methyl quinolinium in rat plasma: Application to pharmacokinetic and oral bioavailability studiesJournal of Pharmaceutical and Biomedical Analysis
- [3]Nicotinamide N-methyltransferase inhibition mimics and boosts exercise-mediated improvements in muscle function in aged miceScientific Reports
- [4]Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunctionBiochemical Pharmacology
- [5]Identification of nicotinamide N-methyltransferase as a promising therapeutic target for sarcopeniaAging Cell
Péptidos relacionados
AOD-9604
Well studiedModified hGH Fragment | Fat Loss Peptide
AOD-9604 is a modified fragment of human growth hormone (amino acids 176-191) that stimulates lipolysis and inhibits lipogenesis without the side effects of full growth hormone.
BAM-15
Moderate researchMitochondrial Uncoupler | Metabolic Enhancer
BAM-15 is a synthetic mitochondrial uncoupler that has emerged as a promising research compound for obesity and metabolic disorders.
Cagrilintide
Extensively studiedLong-Acting Amylin Receptor Agonist | Weight Loss & Diabetes
Novel long-acting lipidated amylin analog functioning as dual amylin and calcitonin receptor agonist for weight management and type 2 diabetes.
HGH Fragment 176-191
Moderate researchGrowth Hormone Fragment | Fat Loss Peptide
HGH Fragment 176-191 is the fat-burning segment of human growth hormone, corresponding to amino acids 176 through 191 of the full GH molecule.